TABLE 3.
Distribution of ESBLs among the clinical isolates of C. freundii, Enterobacter spp. and S. marcescens collected from three university hospitals in Korea
| Species | No. of strains | No. DDST+a | ESBL (no. of isolates)
|
||||
|---|---|---|---|---|---|---|---|
| TEM type | SHV type | CTX-M type | AmpC typeb | Mixed ESBLs | |||
| C. freundii | 4 | 4 | SHV-2a | CTX-M3/OXA-1 like | |||
| TEM-1/SHV-Nc (2) | |||||||
| E. aerogenes | 6 | 6 | TEM-1/SHV-1/CTX-M-15/OXA-1 like (3) | SHV-11/DHA-1 (3) | |||
| E. cloacae | 7 | 5 | SHV-12 (3) | CTX-M-9 | TEM-52/DHA-1 | ||
| TEM-1/SHV-12/ACT-1 | |||||||
| SHV-12/CTX-M-9 | |||||||
| S. marcescens | 22 | 22 | TEM-52 (9) | SHV-12 (3) | CTX-M3(4) | ||
| TEM-52/OXA-1 like | CTX-M3/OXA-1-like (5) | ||||||
| Total no. of strains | 39 | 37 | 10 | 9 | 14 | 3 | 3 |
a
Number of strains positive by the double-disk synergy test (DDST).
b
Plasmid-mediated AmpC-type β-lactamases.
c
SHV-N is a novel SHV-derived ESBL with a pI of 7.6.